Table 1.
Baseline characteristics of the study population
| All | SR | AF | |
|---|---|---|---|
| Age (years), median (IQR) | 78 (13) | 77 (14) | 79 (13) |
| Range (low:high) | 31:95 | 31:95 | 35:95 |
| Sex male:female | 324:268 | 191:153 | 133:115 |
| Study centre Basel: Greifswald | 331:261 | ||
| ECG rhythm SR:AF | 344:248 | ||
| Hypertension (%) | 427 (72.1) | 241 (70.1) | 186 (75.0) |
| Heart failure (%) | 222 (37.5) | 95 (27.6) | 127 (51.2) |
| Diabetes (%) | 185 (31.3) | 101 (29.4) | 84 (33.9) |
| Stroke (%) | 94 (15.9) | 44 (12.8) | 50 (20.2) |
| CHA2DS2-VASc mean points | 4.02 | 3.79 | 4.26 |
| OACs (%) | 288 (48.6) | 116 (33.7) | 172 (69.4) |
| Antiplatelet therapy (%) | 226 (38.2) | 161 (46.8) | 65 (26.2) |
| Aspirin (%) | 207 (35) | 151 (43.9) | 56 (22.6) |
| Clopidogrel (%) | 57 (9.6) | 32 (9.3) | 25 (10.1) |
| Antiarrhythmic therapy (%) | 81 (13.7) | 36 (10.5) | 45 (18.1) |
| Amiodarone (%) | 29 (4.9) | 19 (5.5) | 10 (4) |
| Others (%) | 52 (8.8) | 17 (4.9) | 35 (14.1) |
| ACE inhibitors (%) | 200 (33.8) | 107 (31.1) | 93 (37.5) |
| ARBs (%) | 170 (28.7) | 99 (28.8) | 71 (28.6) |
| CCB (%) | 151 (25.5) | 97 (28.2) | 54 (21.8) |
| Beta blockers (%) | 414 (69.9) | 218 (63.4) | 196 (79) |
| Diuretics (%) | 370 (62.5) | 180 (52.3) | 190 (76.1) |
AF, atrial fibrillation; ACE, angiotensin converting enzyme; ARBs, angiotensin II receptor blockers; CCBs, calcium channel blockers; ECG, electrocardiogram; IQR, interquartile range; OAC, oral anticoagulant; SR, sinus rhythm.